{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:31:31Z","timestamp":1782210691395,"version":"3.54.5"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11886-9","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:16:29Z","timestamp":1778501789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long non-coding RNAs as modulators of endocrine therapy response in hormone receptor-positive breast cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Supriya","family":"Shukla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manika P.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Rashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"6","key":"11886_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J et al (2024) Breast cancer statistics 2024. CA Cancer J Clin 74(6):477\u2013495. https:\/\/doi.org\/10.3322\/caac.21863","journal-title":"CA Cancer J Clin"},{"key":"11886_CR2","doi-asserted-by":"publisher","unstructured":"Orrantia-Borunda E, Anchondo-Nu\u00f1ez P, Acu\u00f1a-Aguilar LE, G\u00f3mez-Valles FO, Ram\u00edrez-Valdespino CA (2022) Subtypes of Breast Cancer. Breast Cancer. Exon 31\u201342. https:\/\/doi.org\/10.36255\/exon-publications-breast-cancer-subtypes","DOI":"10.36255\/exon-publications-breast-cancer-subtypes"},{"issue":"10","key":"11886_CR3","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/ijc.34849","volume":"154","author":"MP Sharma","year":"2024","unstructured":"Sharma MP, Shukla S, Misra G (2024) Recent advances in breast cancer cell line research. Int J Cancer 154(10):1683\u20131693. https:\/\/doi.org\/10.1002\/ijc.34849","journal-title":"Int J Cancer"},{"issue":"9","key":"11886_CR4","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.annonc.2024.06.009","volume":"35","author":"L Arecco","year":"2024","unstructured":"Arecco L, Bruzzone M, Bas R, Kim HJ, Di Meglio A, Bernstein-Molho R et al (2024) Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers. Ann Oncol 35(9):792\u2013804. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.009","journal-title":"Ann Oncol"},{"issue":"4","key":"11886_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4103\/IJPM.IJPM_606_20","volume":"64","author":"F Senel","year":"2021","unstructured":"Senel F (2021) The hormone receptor status in breast cancer and the relationship of subtypes with clinicopathological features. Indian J Pathol Microbiol 64(4):671\u2013676. https:\/\/doi.org\/10.4103\/IJPM.IJPM_606_20","journal-title":"Indian J Pathol Microbiol"},{"issue":"1","key":"11886_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12929-024-01038-1","volume":"31","author":"S Sharma","year":"2024","unstructured":"Sharma S, Houfani AA, Foster LJ (2024) Pivotal functions and impact of long con-coding RNAs on cellular processes and genome integrity. J Biomed Sci 31(1):52. https:\/\/doi.org\/10.1186\/s12929-024-01038-1","journal-title":"J Biomed Sci"},{"issue":"3","key":"11886_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/ncrna5030046","volume":"5","author":"A Goustin","year":"2019","unstructured":"Goustin A, Thepsuwan P, Kosir M, Lipovich L (2019) The Growth-Arrest-Specific (GAS)-5 Long Non-Coding RNA: A Fascinating lncRNA Widely Expressed in Cancers. Noncoding RNA 5(3):46. https:\/\/doi.org\/10.3390\/ncrna5030046","journal-title":"Noncoding RNA"},{"issue":"10","key":"11886_CR8","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.celrep.2020.107753","volume":"31","author":"X Lin","year":"2020","unstructured":"Lin X, Dinglin X, Cao S, Zheng S, Wu C, Chen W et al (2020) Enhancer-Driven lncRNA BDNF-AS Induces Endocrine Resistance and Malignant Progression of Breast Cancer through the RNH1\/TRIM21\/mTOR Cascade. Cell Rep 31(10):107753. https:\/\/doi.org\/10.1016\/j.celrep.2020.107753","journal-title":"Cell Rep"},{"issue":"2","key":"11886_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s13353-023-00807-2","volume":"65","author":"J Mi","year":"2024","unstructured":"Mi J, Zhang H, Jiang X, Yi Y, Cao W, Song C et al (2024) lncRNA MIAT promotes luminal B breast cancer cell proliferation, migration, and invasion in vitro. J Appl Genet 65(2):309\u2013319. https:\/\/doi.org\/10.1007\/s13353-023-00807-2","journal-title":"J Appl Genet"},{"issue":"20","key":"11886_CR10","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1158\/0008-5472.CAN-20-1031","volume":"80","author":"Z Fang","year":"2020","unstructured":"Fang Z, Wang Y, Wang Z, Xu M, Ren S, Yang D et al (2020) ERINA Is an Estrogen-Responsive LncRNA That Drives Breast Cancer through the E2F1\/RB1 Pathway. Cancer Res 80(20):4399\u20134413. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1031","journal-title":"Cancer Res"},{"issue":"2","key":"11886_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ajhg.2017.07.007","volume":"101","author":"JA Betts","year":"2017","unstructured":"Betts JA, Moradi Marjaneh M, Al-Ejeh F, Lim YC, Shi W, Sivakumaran H et al (2017) Long Noncoding RNAs CUPID1 and CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage. Am J Hum Genet 101(2):255\u2013266. https:\/\/doi.org\/10.1016\/j.ajhg.2017.07.007","journal-title":"Am J Hum Genet"},{"issue":"2","key":"11886_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","volume":"22","author":"L Statello","year":"2021","unstructured":"Statello L, Guo CJ, Chen LL, Huarte M (2021) Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol 22(2):96\u2013118. https:\/\/doi.org\/10.1038\/s41580-020-00315-9","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"11886_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41420-024-01832-8","volume":"10","author":"Y Xia","year":"2024","unstructured":"Xia Y, Pei T, Zhao J, Wang Z, Shen Y, Yang Y et al (2024) Long noncoding RNA H19: functions and mechanisms in regulating programmed cell death in cancer. Cell Death Discov 10(1):76. https:\/\/doi.org\/10.1038\/s41420-024-01832-8 PubMed PMID: 38355574","journal-title":"Cell Death Discov"},{"key":"11886_CR14","doi-asserted-by":"publisher","first-page":"608975","DOI":"10.3389\/fonc.2020.608975","volume":"10","author":"S Ghafouri-Fard","year":"2020","unstructured":"Ghafouri-Fard S, Shoorei H, Anamag FT, Taheri M (2020) The Role of Non-Coding RNAs in Controlling Cell Cycle Related Proteins in Cancer Cells. Front Oncol 10:608975. https:\/\/doi.org\/10.3389\/fonc.2020.608975 PubMed PMID: 33330110","journal-title":"Front Oncol"},{"key":"11886_CR15","doi-asserted-by":"publisher","unstructured":"Dudas J, Ladanyi A, Ingruber J, Steinbichler TB, Riechelmann H (2020) Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio\/Chemoresistance. Cells 9(2). https:\/\/doi.org\/10.3390\/cells9020428 PubMed PMID: 32059478","DOI":"10.3390\/cells9020428"},{"issue":"1","key":"11886_CR16","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1038\/s41467-019-11378-4","volume":"10","author":"MOA Abdalla","year":"2019","unstructured":"Abdalla MOA, Yamamoto T, Maehara K, Nogami J, Ohkawa Y, Miura H et al (2019) The Eleanor ncRNAs activate the topological domain of the ESR1 locus to balance against apoptosis. Nat Commun 10(1):3778. https:\/\/doi.org\/10.1038\/s41467-019-11378-4","journal-title":"Nat Commun"},{"issue":"21","key":"11886_CR17","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1038\/onc.2015.340","volume":"35","author":"X Xue","year":"2016","unstructured":"Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B et al (2016) LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene 35(21):2746\u20132755. https:\/\/doi.org\/10.1038\/onc.2015.340","journal-title":"Oncogene"},{"issue":"1","key":"11886_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/cdd.2016.95","volume":"24","author":"Z Li","year":"2017","unstructured":"Li Z, Hou P, Fan D, Dong M, Ma M, Li H et al (2017) The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. Cell Death Differ 24(1):59\u201371. https:\/\/doi.org\/10.1038\/cdd.2016.95","journal-title":"Cell Death Differ"},{"key":"11886_CR19","doi-asserted-by":"publisher","first-page":"6966","DOI":"10.1038\/ncomms7966","volume":"6","author":"S Tomita","year":"2015","unstructured":"Tomita S, Abdalla MOA, Fujiwara S, Matsumori H, Maehara K, Ohkawa Y et al (2015) A cluster of noncoding RNAs activates the ESR1 locus during breast cancer adaptation. Nat Commun 6:6966. https:\/\/doi.org\/10.1038\/ncomms7966 PubMed PMID: 25923108","journal-title":"Nat Commun"},{"issue":"4","key":"11886_CR20","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/nar\/gkad1142","volume":"52","author":"C Diener","year":"2024","unstructured":"Diener C, Keller A, Meese E (2024) The miRNA\u2013target interactions: An underestimated intricacy. Nucleic Acids Res 52(4):1544\u20131557. https:\/\/doi.org\/10.1093\/nar\/gkad1142","journal-title":"Nucleic Acids Res"},{"key":"11886_CR21","doi-asserted-by":"publisher","unstructured":"Gao L, Shen K, Yin N, Jiang M (2020) Comprehensive Transcriptomic Analysis Reveals Dysregulated Competing Endogenous RNA Network in Endocrine Resistant Breast Cancer Cells. Front Oncol 10. https:\/\/doi.org\/10.3389\/fonc.2020.600487","DOI":"10.3389\/fonc.2020.600487"},{"issue":"11","key":"11886_CR22","doi-asserted-by":"publisher","first-page":"14733","DOI":"10.1007\/s13277-016-5348-8","volume":"37","author":"X Li","year":"2016","unstructured":"Li X, Wu Y, Liu A, Tang X (2016) Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1\u03b1 feedback regulatory loop. Tumor Biology 37(11):14733\u201314743. https:\/\/doi.org\/10.1007\/s13277-016-5348-8","journal-title":"Tumor Biology"},{"issue":"2","key":"11886_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00280-016-3208-2","volume":"79","author":"HY Zhang","year":"2017","unstructured":"Zhang HY, Liang F, Zhang JW, Wang F, Wang L, Kang XG (2017) Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205. Cancer Chemother Pharmacol 79(2):327\u2013337. https:\/\/doi.org\/10.1007\/s00280-016-3208-2","journal-title":"Cancer Chemother Pharmacol"},{"key":"11886_CR24","doi-asserted-by":"publisher","unstructured":"Liu Y, Li M, Yu H, Piao H (2019 Dec) lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR-125a-5p. Int J Mol Med 16. https:\/\/doi.org\/10.3892\/ijmm.2019.4428","DOI":"10.3892\/ijmm.2019.4428"},{"issue":"3","key":"11886_CR25","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1002\/jcp.27105","volume":"234","author":"Y Ma","year":"2019","unstructured":"Ma Y, Bu D, Long J, Chai W, Dong J (2019) LncRNA DSCAM-AS1 acts as a sponge of miR\u2010137 to enhance Tamoxifen resistance in breast cancer. J Cell Physiol 234(3):2880\u20132894. https:\/\/doi.org\/10.1002\/jcp.27105","journal-title":"J Cell Physiol"},{"key":"11886_CR26","doi-asserted-by":"publisher","unstructured":"Yuan J, Yang L, Li Z, Zhang H, Wang Q, Huang J et al (2023) The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer. Front Endocrinol (Lausanne) 14. https:\/\/doi.org\/10.3389\/fendo.2023.1261283","DOI":"10.3389\/fendo.2023.1261283"},{"issue":"1","key":"11886_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13046-025-03529-x","volume":"44","author":"C Wu","year":"2025","unstructured":"Wu C, Sun X, Lu Y, Wang H, Yu Z, Wang Z et al (2025) Cancer-associated fibroblast promotes tamoxifen resistance in estrogen receptor positive breast cancer via exosomal LncRNA PRKCQ-AS1\/miR-200a-3p\/MKP1 axis-mediated apoptosis suppression. J Experimental Clin Cancer Res 44(1):274. https:\/\/doi.org\/10.1186\/s13046-025-03529-x","journal-title":"J Experimental Clin Cancer Res"},{"key":"11886_CR28","doi-asserted-by":"publisher","unstructured":"Kumar V, Vashishta M, Kong L, Wu X, Lu JJ, Guha C et al (2021) The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies. Front Cell Dev Biol 9. https:\/\/doi.org\/10.3389\/fcell.2021.650772","DOI":"10.3389\/fcell.2021.650772"},{"key":"11886_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ijbiomac.2018.06.033","volume":"118","author":"X Pei","year":"2018","unstructured":"Pei X, Wang X, Li H (2018) LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448\/IDO. Int J Biol Macromol 118:24\u201330. https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.06.033","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"11886_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41392-020-0129-7","volume":"5","author":"C Ni","year":"2020","unstructured":"Ni C, Fang QQ, Chen WZ, Jiang JX, Jiang Z, Ye J et al (2020) Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73\u2009+\u2009\u03b3\u03b41 Treg cells. Signal Transduct Target Ther 5(1):41. https:\/\/doi.org\/10.1038\/s41392-020-0129-7 PubMed PMID: 32345959","journal-title":"Signal Transduct Target Ther"},{"key":"11886_CR31","doi-asserted-by":"publisher","unstructured":"Liu SQ, Zhou ZY, Dong X, Guo L, Zhang KJ (2020) LncRNA GNAS-AS1 facilitates ER+ breast cancer cells progression by promoting M2 macrophage polarization via regulating miR-433-3p\/GATA3 axis. Biosci Rep 40(7). https:\/\/doi.org\/10.1042\/BSR20200626","DOI":"10.1042\/BSR20200626"},{"issue":"5","key":"11886_CR32","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00262-020-02511-0","volume":"69","author":"L Zhou","year":"2020","unstructured":"Zhou L, Tian Y, Guo F, Yu B, Li J, Xu H et al (2020) LincRNA-p21 knockdown reversed tumor-associated macrophages function by promoting MDM2 to antagonize* p53 activation and alleviate breast cancer development. Cancer Immunol Immunother 69(5):835\u2013846. https:\/\/doi.org\/10.1007\/s00262-020-02511-0","journal-title":"Cancer Immunol Immunother"},{"issue":"24","key":"11886_CR33","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.21037\/atm-22-6158","volume":"10","author":"M Yang","year":"2022","unstructured":"Yang M, Sun Y, Ji H, Zhang Q (2022) Identification and validation of endocrine resistance-related and immune-related long non-coding RNA (lncRNA) signatures for predicting endocrinotherapy response and prognosis in breast cancer. Ann Transl Med 10(24):1399\u20131399. https:\/\/doi.org\/10.21037\/atm-22-6158","journal-title":"Ann Transl Med"},{"issue":"1","key":"11886_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-019-0747-0","volume":"12","author":"J Wang","year":"2019","unstructured":"Wang J, Xie S, Yang J, Xiong H, Jia Y, Zhou Y et al (2019) The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. J Hematol Oncol 12(1):81. https:\/\/doi.org\/10.1186\/s13045-019-0747-0","journal-title":"J Hematol Oncol"},{"issue":"12","key":"11886_CR35","doi-asserted-by":"publisher","first-page":"e0168406","DOI":"10.1371\/journal.pone.0168406","volume":"11","author":"H Liu","year":"2016","unstructured":"Liu H, Wang G, Yang L, Qu J, Yang Z, Zhou X (2016) Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt\/\u03b2-Catenin Pathway. PLoS ONE 11(12):e0168406. https:\/\/doi.org\/10.1371\/journal.pone.0168406","journal-title":"PLoS ONE"},{"issue":"21","key":"11886_CR36","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.3390\/cancers14215206","volume":"14","author":"R Ozyurt","year":"2022","unstructured":"Ozyurt R, Ozpolat B (2022) Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies. Cancers (Basel) 14(21):5206. https:\/\/doi.org\/10.3390\/cancers14215206","journal-title":"Cancers (Basel)"},{"key":"11886_CR37","doi-asserted-by":"publisher","first-page":"133853","DOI":"10.1016\/j.molstruc.2022.133853","volume":"1270","author":"S Das","year":"2022","unstructured":"Das S, Kulkarni S, Singh Y, Kumar P, Thareja S (2022) Selective Estrogen Receptor Modulators (SERMs) for the treatment of ER+ breast cancer: An overview. J Mol Struct 1270:133853. https:\/\/doi.org\/10.1016\/j.molstruc.2022.133853","journal-title":"J Mol Struct"},{"issue":"15","key":"11886_CR38","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.3390\/ijms22157812","volume":"22","author":"C Hernando","year":"2021","unstructured":"Hernando C, Ortega-Morillo B, Tapia M, Morag\u00f3n S, Mart\u00ednez MT, Eroles P et al (2021) Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. Int J Mol Sci 22(15):7812. https:\/\/doi.org\/10.3390\/ijms22157812","journal-title":"Int J Mol Sci"},{"key":"11886_CR39","doi-asserted-by":"publisher","first-page":"102825","DOI":"10.1016\/j.ctrv.2024.102825","volume":"130","author":"M Gheysen","year":"2024","unstructured":"Gheysen M, Punie K, Wildiers H, Neven P (2024) Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review. Cancer Treat Rev 130:102825. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102825","journal-title":"Cancer Treat Rev"},{"issue":"16","key":"11886_CR40","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1158\/1078-0432.CCR-16-2561","volume":"23","author":"T Bihani","year":"2017","unstructured":"Bihani T, Patel HK, Arlt H, Tao N, Jiang H, Brown JL et al (2017) Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), has antitumor activity in multiple ER+ breast cancer patient-derived xenograft models. Clin Cancer Res 23(16):4793\u20134804. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2561 PubMed PMID: 28473534","journal-title":"Clin Cancer Res"},{"issue":"16","key":"11886_CR41","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","volume":"30","author":"SM Gough","year":"2024","unstructured":"Gough SM, Flanagan JJ, Teh J, Andreoli M, Rousseau E, Pannone M et al (2024) Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4\/6 or PI3K\/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clin Cancer Res 30(16):3549\u20133563. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3465 PubMed PMID: 38819400","journal-title":"Clin Cancer Res"},{"key":"11886_CR42","doi-asserted-by":"publisher","first-page":"106729","DOI":"10.1016\/j.jsbmb.2025.106729","volume":"250","author":"K Bhutani","year":"2025","unstructured":"Bhutani K, Vishwakarma S, Yadav P, Yadav MK (2025) The current landscape of aromatase inhibitors for the treatment of estrogen receptor-positive breast carcinoma. J Steroid Biochem Mol Biol 250:106729. https:\/\/doi.org\/10.1016\/j.jsbmb.2025.106729","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"9","key":"11886_CR43","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","volume":"31","author":"X Wang","year":"2024","unstructured":"Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M (2024) Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer. Cancer Gene Ther 31(9):1283\u20131291. https:\/\/doi.org\/10.1038\/s41417-024-00747-x","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"11886_CR44","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","volume":"24","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q et al (2023) Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 24(6):646\u2013657. https:\/\/doi.org\/10.1016\/S1470-2045(23)00172-9","journal-title":"Lancet Oncol"},{"key":"11886_CR45","doi-asserted-by":"publisher","first-page":"101103","DOI":"10.1016\/j.drup.2024.101103","volume":"76","author":"A Glaviano","year":"2024","unstructured":"Glaviano A, Wander SA, Baird RD, Yap KCH, Lam HY, Toi M et al (2024) Mechanisms of sensitivity and resistance to CDK4\/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resist Updates 76:101103. https:\/\/doi.org\/10.1016\/j.drup.2024.101103","journal-title":"Drug Resist Updates"},{"issue":"1","key":"11886_CR46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW et al (2021) Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther 6(1):425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"11886_CR47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/cancers17010016","volume":"17","author":"L Liu","year":"2024","unstructured":"Liu L, Graff SL, Wang Y (2024) New Emerging Therapies Targeting PI3K\/AKT\/mTOR\/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer\u2014Current State and Molecular Pathology Perspective. Cancers (Basel) 17(1):16. https:\/\/doi.org\/10.3390\/cancers17010016","journal-title":"Cancers (Basel)"},{"issue":"2","key":"11886_CR48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","volume":"32","author":"F Andr\u00e9","year":"2021","unstructured":"Andr\u00e9 F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA et al (2021) Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2\u2013negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 32(2):208\u2013217. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.011","journal-title":"Ann Oncol"},{"key":"11886_CR49","doi-asserted-by":"publisher","first-page":"1249160","DOI":"10.3389\/fonc.2023.1249160","volume":"13","author":"D Generali","year":"2023","unstructured":"Generali D, Berardi R, Caruso M, Cazzaniga M, Garrone O, Minchella I et al (2023) Aromatase inhibitors: the journey from the state of the art to clinical open questions. Front Oncol 13:1249160. https:\/\/doi.org\/10.3389\/fonc.2023.1249160 PubMed PMID: 38188305","journal-title":"Front Oncol"},{"key":"11886_CR50","doi-asserted-by":"publisher","unstructured":"Li Z, Yu D, Li H, Lv Y, Li S (2019 Jan) Long non-coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2\/p21 axis and the PI3K\/AKT signaling pathway. Int J Oncol 8. https:\/\/doi.org\/10.3892\/ijo.2019.4679","DOI":"10.3892\/ijo.2019.4679"},{"key":"11886_CR51","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.2147\/IJGM.S320998","volume":"14","author":"M Zhang","year":"2021","unstructured":"Zhang M, Wu K, Zhang P, Qiu Y, Bai F, Chen H (2021) HOTAIR Facilitates Endocrine Resistance in Breast Cancer Through ESR1\/miR-130b-3p Axis: Comprehensive Analysis of mRNA-miRNA-lncRNA Network. Int J Gen Med 14:4653\u20134663. https:\/\/doi.org\/10.2147\/IJGM.S320998PMID: 34434057","journal-title":"Int J Gen Med"},{"key":"11886_CR52","doi-asserted-by":"publisher","unstructured":"Chen X, Ding J, Hu G, Shu X, Liu Y, Du J et al (2023) Estrogen-Induced LncRNA, LINC02568, Promotes Estrogen Receptor\u2010Positive Breast Cancer Development and Drug Resistance Through Both In Trans and In Cis Mechanisms. Adv Sci 10(25). https:\/\/doi.org\/10.1002\/advs.202206663","DOI":"10.1002\/advs.202206663"},{"issue":"22","key":"11886_CR53","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.3390\/cells11223610","volume":"11","author":"K Horie","year":"2022","unstructured":"Horie K, Takagi K, Takeiwa T, Mitobe Y, Kawabata H, Suzuki T et al (2022) Estrogen-Inducible LncRNA BNAT1 Functions as a Modulator for Estrogen Receptor Signaling in Endocrine-Resistant Breast Cancer Cells. Cells 11(22):3610. https:\/\/doi.org\/10.3390\/cells11223610","journal-title":"Cells"},{"issue":"1","key":"11886_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3892\/etm.2021.10934","volume":"23","author":"H Sun","year":"2021","unstructured":"Sun H, Wang G, Cai J, Wei X, Zeng Y, Peng Y et al (2021) Long non-coding RNA H19 mediates N-acetyltransferase 1 gene methylation in the development of tamoxifen resistance in breast cancer. Exp Ther Med 23(1):12. https:\/\/doi.org\/10.3892\/etm.2021.10934","journal-title":"Exp Ther Med"},{"issue":"19","key":"11886_CR55","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1158\/0008-5472.CAN-23-0015","volume":"83","author":"S Yu","year":"2023","unstructured":"Yu S, Wang Y, Gong X, Fan Z, Wang Z, Liang Z et al (2023) LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity. Cancer Res 83(19):3220\u20133236. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0015","journal-title":"Cancer Res"},{"issue":"1","key":"11886_CR56","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1515\/med-2021-0012","volume":"16","author":"H Zhang","year":"2020","unstructured":"Zhang H, Zhang J, Dong L, Ma R (2020) LncRNA ATXN8OS enhances tamoxifen resistance in breast cancer. Open Med 16(1):68\u201380. https:\/\/doi.org\/10.1515\/med-2021-0012","journal-title":"Open Med"},{"issue":"5","key":"11886_CR57","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1007\/s11033-022-07244-0","volume":"49","author":"X Liang","year":"2022","unstructured":"Liang X, Zhao Y, Fang Z, Shao N, Zhai D, Zhang M et al (2022) DLGAP1-AS2 promotes estrogen receptor signalling and confers tamoxifen resistance in breast cancer. Mol Biol Rep 49(5):3939\u20133947. https:\/\/doi.org\/10.1007\/s11033-022-07244-0","journal-title":"Mol Biol Rep"},{"issue":"9","key":"11886_CR58","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3390\/biomedicines13092087","volume":"13","author":"J Lee","year":"2025","unstructured":"Lee J, Kang B, Kim EA, Kang J, Chae YS, Park HY et al (2025) Differential Expression of Long Non-Coding RNA IGF2-AS in Tamoxifen-Resistant Breast Cancer Cells. Biomedicines 13(9):2087. https:\/\/doi.org\/10.3390\/biomedicines13092087","journal-title":"Biomedicines"},{"issue":"4","key":"11886_CR59","first-page":"2267","volume":"14","author":"J Fang","year":"2022","unstructured":"Fang J, Li K, Huang C, Xue H, Ni Q (2022) LncRNA TTN-AS1 confers tamoxifen resistance in breast cancer via sponging miR-107 to modulate PI3K\/AKT signaling pathway. Am J Transl Res 14(4):2267\u20132279 PubMed PMID: 35559394","journal-title":"Am J Transl Res"},{"key":"11886_CR60","doi-asserted-by":"publisher","unstructured":"Khan MI, Ahmad A (2022) LncRNA SNHG6 sponges miR-101 and induces tamoxifen resistance in breast cancer cells through induction of EMT. Front Oncol 12. https:\/\/doi.org\/10.3389\/fonc.2022.1015428","DOI":"10.3389\/fonc.2022.1015428"},{"key":"11886_CR61","doi-asserted-by":"publisher","unstructured":"Mitobe Y, Ikeda K, Suzuki T, Takagi K, Kawabata H, Horie-Inoue K et al (2019) ESR1 -Stabilizing Long Noncoding RNA TMPO-AS1 Promotes Hormone-Refractory Breast Cancer Progression. Mol Cell Biol 39(23). https:\/\/doi.org\/10.1128\/MCB.00261-19","DOI":"10.1128\/MCB.00261-19"},{"key":"11886_CR62","doi-asserted-by":"publisher","first-page":"109536","DOI":"10.1016\/j.cellsig.2020.109536","volume":"68","author":"T Ma","year":"2020","unstructured":"Ma T, Liang Y, Li Y, Song X, Zhang N, Li X et al (2020) LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer. Cell Signal 68:109536. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109536","journal-title":"Cell Signal"},{"issue":"25","key":"11886_CR63","doi-asserted-by":"publisher","first-page":"37957","DOI":"10.18632\/oncotarget.9364","volume":"7","author":"Nsi Huang","year":"2016","unstructured":"Huang Nsi, Chi Y, yun, Xue Jyan, Liu M, ying, Huang S, Mo M et al (2016) Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer. Oncotarget 7(25):37957\u201337965. https:\/\/doi.org\/10.18632\/oncotarget.9364","journal-title":"Oncotarget"},{"issue":"1","key":"11886_CR64","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41419-024-07301-5","volume":"16","author":"WX Peng","year":"2025","unstructured":"Peng WX, Koirala P, Zhou H, Jiang J, Zhang Z, Yang L et al (2025) Correction: Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer. Cell Death Dis 16(1):10. https:\/\/doi.org\/10.1038\/s41419-024-07301-5","journal-title":"Cell Death Dis"},{"issue":"1","key":"11886_CR65","doi-asserted-by":"publisher","first-page":"7160","DOI":"10.1038\/s41467-022-34702-x","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Luo R, Zhang Y, Ye S, Zeng X, Liu J et al (2022) Long noncoding RNA DIO3OS induces glycolytic-dominant metabolic reprogramming to promote aromatase inhibitor resistance in breast cancer. Nat Commun 13(1):7160. https:\/\/doi.org\/10.1038\/s41467-022-34702-x","journal-title":"Nat Commun"},{"issue":"20","key":"11886_CR66","doi-asserted-by":"publisher","first-page":"20658","DOI":"10.18632\/aging.103966","volume":"12","author":"J Feng","year":"2020","unstructured":"Feng J, Wen T, Li Z, Feng L, Zhou L, Yang Z et al (2020) Cross-talk between the ER pathway and the lncRNA MAFG-AS1\/miR-339-5p\/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance. Aging 12(20):20658\u201320683. https:\/\/doi.org\/10.18632\/aging.103966","journal-title":"Aging"},{"issue":"12","key":"11886_CR67","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.7150\/jca.38728","volume":"11","author":"CY Kim","year":"2020","unstructured":"Kim CY, Oh JH, Lee JY, Kim MH (2020) The LncRNA HOTAIRM1 Promotes Tamoxifen Resistance by Mediating HOXA1 Expression in ER+ Breast Cancer Cells. J Cancer 11(12):3416\u20133423. https:\/\/doi.org\/10.7150\/jca.38728","journal-title":"J Cancer"},{"issue":"6","key":"11886_CR68","doi-asserted-by":"publisher","first-page":"101042831770579","DOI":"10.1177\/1010428317705790","volume":"39","author":"Y Li","year":"2017","unstructured":"Li Y, Jiang B, Zhu H, Qu X, Zhao L, Tan Y et al (2017) Inhibition of long non-coding RNA ROR reverses resistance to Tamoxifen by inducing autophagy in breast cancer. Tumor Biology 39(6):101042831770579. https:\/\/doi.org\/10.1177\/1010428317705790","journal-title":"Tumor Biology"},{"issue":"3","key":"11886_CR69","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1158\/0008-5472.CAN-21-1155","volume":"82","author":"H Yuan","year":"2022","unstructured":"Yuan H, Yan L, Wu M, Shang Y, Guo Q, Ma X et al (2022) Analysis of the Estrogen Receptor-Associated LncRNA Landscape Identifies a Role for ERLC1 in Breast Cancer Progression. Cancer Res 82(3):391\u2013405. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1155 PubMed PMID: 34810200","journal-title":"Cancer Res"},{"issue":"1","key":"11886_CR70","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12860-024-00510-y","volume":"25","author":"J Lee","year":"2024","unstructured":"Lee J, Kim EA, Kang J, Chae YS, Park HY, Kang B et al (2024) Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer. BMC Mol Cell Biol 25(1):12. https:\/\/doi.org\/10.1186\/s12860-024-00510-y","journal-title":"BMC Mol Cell Biol"},{"issue":"6","key":"11886_CR71","doi-asserted-by":"publisher","first-page":"366","DOI":"10.21037\/atm-22-795","volume":"10","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Qian T, Li S, Xie Y, Tao M (2022) Metformin reverses tamoxifen resistance through the lncRNA GAS5-medicated mTOR pathway in breast cancer. Ann Transl Med 10(6):366. https:\/\/doi.org\/10.21037\/atm-22-795 PubMed PMID: 35434034","journal-title":"Ann Transl Med"},{"key":"11886_CR72","doi-asserted-by":"publisher","unstructured":"Kim HW, Baek M, Jung S, Jang S, Lee H, Yang SH et al (2023) ELOVL2-AS1 suppresses tamoxifen resistance by sponging miR-1233-3p in breast cancer. Epigenetics 18(1). https:\/\/doi.org\/10.1080\/15592294.2023.2276384","DOI":"10.1080\/15592294.2023.2276384"},{"issue":"3","key":"11886_CR73","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10549-023-07138-0","volume":"203","author":"L Lei","year":"2024","unstructured":"Lei L, Huang Y, Shi L, Ye W, Lv X, Ying L et al (2024) Palbociclib sensitizes ER-positive breast cancer cells to fulvestrant by promoting the ubiquitin-mediated degradation of ER-\u03b1 via SNHG17\/Hippo-YAP axis. Breast Cancer Res Treat 203(3):613\u2013625. https:\/\/doi.org\/10.1007\/s10549-023-07138-0","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"11886_CR74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13058-019-1130-3","volume":"21","author":"J Cairns","year":"2019","unstructured":"Cairns J, Ingle JN, Kalari KR, Shepherd LE, Kubo M, Goetz MP et al (2019) The lncRNA MIR2052HG regulates ER\u03b1 levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. Breast Cancer Res 21(1):47. https:\/\/doi.org\/10.1186\/s13058-019-1130-3","journal-title":"Breast Cancer Res"},{"key":"11886_CR75","doi-asserted-by":"publisher","first-page":"1458588","DOI":"10.3389\/fonc","volume":"14","author":"Y Yan","year":"2024","unstructured":"Yan Y, Zhang J (2024) Mechanisms of tamoxifen resistance: insight from long non-coding RNAs. Front Oncol 14:1458588. https:\/\/doi.org\/10.3389\/fonc2024.1458588 PubMed PMID: 39439957","journal-title":"Front Oncol"},{"key":"11886_CR76","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.12659\/MSM.900689","volume":"22","author":"C Wu","year":"2016","unstructured":"Wu C, Luo J (2016) Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway. Med Sci Monit 22:3860\u20133867. https:\/\/doi.org\/10.12659\/MSM.900689","journal-title":"Med Sci Monit"},{"issue":"4","key":"11886_CR77","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.clbc.2024.02.007","volume":"24","author":"M Liao","year":"2024","unstructured":"Liao M, Webster J, Coonrod EM, Weilbaecher KN, Maher CA, White NM (2024) BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer. Clin Breast Cancer 24(4):368\u2013375e2. https:\/\/doi.org\/10.1016\/j.clbc.2024.02.007","journal-title":"Clin Breast Cancer"},{"key":"11886_CR78","doi-asserted-by":"publisher","first-page":"101602","DOI":"10.1016\/j.tranon.2022.101602","volume":"28","author":"X Wen","year":"2023","unstructured":"Wen X, Wu Y, Lou Y, Xia Y, Yu X (2023) The roles of Linc-ROR in the regulation of cancer stem cells. Transl Oncol 28:101602. https:\/\/doi.org\/10.1016\/j.tranon.2022.101602","journal-title":"Transl Oncol"},{"issue":"1","key":"11886_CR79","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1038\/s41467-020-19349-w","volume":"11","author":"Q Shi","year":"2020","unstructured":"Shi Q, Li Y, Li S, Jin L, Lai H, Wu Y et al (2020) LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. Nat Commun 11(1):5513. https:\/\/doi.org\/10.1038\/s41467-020-19349-w","journal-title":"Nat Commun"},{"issue":"4","key":"11886_CR80","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1159\/000495643","volume":"51","author":"P Basak","year":"2018","unstructured":"Basak P, Chatterjee S, Bhat V, Su A, Jin H, Lee-Wing V et al (2018) Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells. Cell Physiol Biochem 51(4):1518\u20131532. https:\/\/doi.org\/10.1159\/000495643","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"11886_CR81","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41419-025-07423-4","volume":"16","author":"V Melone","year":"2025","unstructured":"Melone V, Palumbo D, Palo L, Brusco N, Salvati A, Tarallo A et al (2025) LncRNA PVT1 links estrogen receptor alpha and the polycomb repressive complex 2 in suppression of pro-apoptotic genes in hormone-responsive breast cancer. Cell Death Dis 16(1):80. https:\/\/doi.org\/10.1038\/s41419-025-07423-4","journal-title":"Cell Death Dis"},{"issue":"1","key":"11886_CR82","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12964-026-02702-9","volume":"24","author":"V Melone","year":"2026","unstructured":"Melone V, Salvati A, Palo L, Palumbo D, Memoli D, Ianniello M et al (2026) Identification of LncRNAs scaffolding a chromatin-associated gene regulatory complex in breast cancer cells comprising ER\u03b1, DOT1L and menin. Cell Communication Signal 24(1):140. https:\/\/doi.org\/10.1186\/s12964-026-02702-9","journal-title":"Cell Communication Signal"},{"issue":"11","key":"11886_CR83","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.18632\/aging.204110","volume":"14","author":"Y Xiang","year":"2022","unstructured":"Xiang Y, Liu H, Hu H, Li LW, Zong QB, Wu TW et al (2022) LINC00094\/miR-19a-3p\/CYP19A1 axis affects the sensitivity of ER positive breast cancer cells to Letrozole through EMT pathway. Aging 14(11):4755\u20134768. https:\/\/doi.org\/10.18632\/aging.204110","journal-title":"Aging"},{"key":"11886_CR84","doi-asserted-by":"publisher","unstructured":"Cai Z, Shi Q, Li Y, Jin L, Li S, Wong LL et al (2023) LncRNA EILA promotes CDK4\/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein. Sci Adv 9(40). https:\/\/doi.org\/10.1126\/sciadv.adi3821","DOI":"10.1126\/sciadv.adi3821"},{"issue":"1","key":"11886_CR85","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12943-020-01210-9","volume":"19","author":"X Jin","year":"2020","unstructured":"Jin X, Ge LP, Li DQ, Shao ZM, Di GH, Xu XE et al (2020) LncRNA TROJAN promotes proliferation and resistance to CDK4\/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer. Mol Cancer 19(1):87. https:\/\/doi.org\/10.1186\/s12943-020-01210-9 PubMed PMID: 32393270","journal-title":"Mol Cancer"},{"issue":"1","key":"11886_CR86","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1021\/acsami.8b18288","volume":"11","author":"N Gong","year":"2019","unstructured":"Gong N, Teng X, Li J, Liang XJ (2019) Antisense Oligonucleotide-Conjugated Nanostructure-Targeting lncRNA MALAT1 Inhibits Cancer Metastasis. ACS Appl Mater Interfaces 11(1):37\u201342. https:\/\/doi.org\/10.1021\/acsami.8b18288 PubMed PMID: 30548064","journal-title":"ACS Appl Mater Interfaces"},{"key":"11886_CR87","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.biopha.2017.03.054","volume":"90","author":"Y Yu","year":"2017","unstructured":"Yu Y, Lv F, Liang D, Yang Q, Zhang B, Lin H et al (2017) HOTAIR may regulate proliferation, apoptosis, migration and invasion of MCF-7 cells through regulating the P53\/Akt\/JNK signaling pathway. Biomed Pharmacother 90:555\u2013561. https:\/\/doi.org\/10.1016\/j.biopha.2017.03.054","journal-title":"Biomed Pharmacother"},{"key":"11886_CR88","doi-asserted-by":"publisher","unstructured":"Liu SJ, Horlbeck MA, Cho SW, Birk HS, Malatesta M, He D et al (2017) CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. Science 355(6320). https:\/\/doi.org\/10.1126\/science.aah7111 PubMed PMID: 27980086","DOI":"10.1126\/science.aah7111"},{"key":"11886_CR89","doi-asserted-by":"publisher","unstructured":"Subhan MA, Filipczak N, Torchilin VP (2023) Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers. Pharmaceuticals (Basel) 16(7). https:\/\/doi.org\/10.3390\/ph16070970 PubMed PMID: 37513882","DOI":"10.3390\/ph16070970"},{"key":"11886_CR90","doi-asserted-by":"publisher","unstructured":"Jiang X, Chen G, Sun L, Liu C, Zhang Y, Liu M et al (2022) Characteristics and survival in bone metastatic breast cancer patients with different hormone receptor status: A population-based cohort study. Front Oncol 12. https:\/\/doi.org\/10.3389\/fonc.2022.977226","DOI":"10.3389\/fonc.2022.977226"},{"issue":"3","key":"11886_CR91","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3390\/cells11030388","volume":"11","author":"H Shao","year":"2022","unstructured":"Shao H, Varamini P (2022) Breast Cancer Bone Metastasis: A Narrative Review of Emerging Targeted Drug Delivery Systems. Cells 11(3):388. https:\/\/doi.org\/10.3390\/cells11030388","journal-title":"Cells"},{"issue":"1","key":"11886_CR92","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12967-025-06156-4","volume":"23","author":"X Liu","year":"2025","unstructured":"Liu X, Ma R, Wei F, Wang M, Jiang Y, Zheng P et al (2025) Tumor-derived exosomal lncRNA-MIR193BHG promotes bone metastasis of breast cancer by targeting the miR-489-3p\/DNMT3A signaling axis in osteoclasts. J Transl Med 23(1):142. https:\/\/doi.org\/10.1186\/s12967-025-06156-4","journal-title":"J Transl Med"},{"key":"11886_CR93","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bonr.2018.06.007","volume":"9","author":"KB Farrell","year":"2018","unstructured":"Farrell KB, Karpeisky A, Thamm DH, Zinnen S (2018) Bisphosphonate conjugation for bone specific drug targeting. Bone Rep 9:47\u201360. https:\/\/doi.org\/10.1016\/j.bonr.2018.06.007","journal-title":"Bone Rep"},{"key":"11886_CR94","doi-asserted-by":"publisher","unstructured":"Shah D, Gandhi S, Shah S, Patel K (2025 Jun) Recent Breakthroughs in Exosome-Based Drug Delivery: A Comprehensive Review for Cancer Therapy. Cancer Biother Radiopharm 12. https:\/\/doi.org\/10.1089\/cbr.2025.0050","DOI":"10.1089\/cbr.2025.0050"},{"issue":"1","key":"11886_CR95","doi-asserted-by":"publisher","first-page":"8567","DOI":"10.1038\/s41598-024-57296-4","volume":"14","author":"F Badparvar","year":"2024","unstructured":"Badparvar F, Marjani AP, Salehi R, Ramezani F (2024) Dual pH\/redox-responsive hyperbranched polymeric nanocarriers with TME-trigger size shrinkage and charge reversible ability for amplified chemotherapy of breast cancer. Sci Rep 14(1):8567. https:\/\/doi.org\/10.1038\/s41598-024-57296-4","journal-title":"Sci Rep"},{"issue":"1","key":"11886_CR96","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/cells9010137","volume":"9","author":"S Bajan","year":"2020","unstructured":"Bajan S, Hutvagner G, RNA-Based Therapeutics (2020) From Antisense Oligonucleotides to miRNAs. Cells 9(1):137. https:\/\/doi.org\/10.3390\/cells9010137","journal-title":"Cells"},{"issue":"4","key":"11886_CR97","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","volume":"27","author":"ST Crooke","year":"2018","unstructured":"Crooke ST, Witztum JL, Bennett CF, Baker BF (2018) RNA-Targeted Therapeutics. Cell Metab 27(4):714\u2013739. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.004","journal-title":"Cell Metab"},{"key":"11886_CR98","doi-asserted-by":"publisher","unstructured":"Maroni P, Gomarasca M, Lombardi G (2023) Long non-coding RNAs in bone metastasis: progresses and perspectives as potential diagnostic and prognostic biomarkers. Front Endocrinol (Lausanne) 14. https:\/\/doi.org\/10.3389\/fendo.2023.1156494","DOI":"10.3389\/fendo.2023.1156494"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11886-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11886-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11886-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:16:30Z","timestamp":1778501790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11886-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11886"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11886-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare they have no financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"736"}}